USA flag logo/image

An Official Website of the United States Government

Economical production of artemisinin precursors

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
71268
Program Year/Program:
2004 / SBIR
Agency Tracking Number:
AI061936
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
AMYRIS BIOTECHNOLOGIES
AMYRIS BIOTECHNOLOGIES 412 B KAINS AVE ALBANY, CA 94706 0126
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2004
Title: Economical production of artemisinin precursors
Agency: HHS
Contract: 1R43AI061936-01
Award Amount: $597,202.00
 

Abstract:

DESCRIPTION (provided by applicant): In many regions of the world, strains of Plasmodium have emerged that are resistant to the current arsenal of antimalarial therapeutics. Artemisinins, terpenoid compounds derived from traditional Chinese medicines used for centuries, have been acclaimed as the next generation of antimalarial drugs because they show little or no cross-resistance with existing antimalarials. While inexpensive by Western standards, artemisinin based treatments remain prohibitively expensive to those in the developing world who need them most. The long term goal of this SBIR-at-NIAID project is to develop an artemisinin production process utilizing a biosynthetically produced synthon, artemisinic acid. Methods for the synthesis of artemisinin from artemisinic acid currently exist, but are not utilized due to the cost of extracting the precursor. This Phase I project will address this problem by proving the feasibility of producing artemisinic acid via a bacterial fermentation. Building on previous work which enabled the production of the artemisinic acid precursor, amorphadiene, at high levels, we will build a production strain that is able to produce economically relevant levels of amorphadiene. We will also isolate, clone, and express the genes, likely encoding cytochrome P450s, responsible for the conversion of amorphadiene to artemisinic acid. Additionally, we will engineer the machinery for efficient catalysis by P450s in E. coli. This research, conducted in collaboration with the University of California, could eventually lead to reductions in the cost of artemisinin based treatments by a factor of 3 or more. This technology could also result in the development of many promising new terpene-based drugs produced at a lower cost to consumers, reduced time to market, and to decreased effect on the environment, in terms of destruction of natural resources and the release of synthetic chemical effluents.

Principal Investigator:

Jack D. Newman
5105043995
NEWMAN@AMYRISBIOTECH.COM

Business Contact:


5105043995
Small Business Information at Submission:

AMYRIS BIOTECHNOLOGIES
AMYRIS BIOTECHNOLOGIES 412 B KAINS AVE ALBANY, CA 94706

EIN/Tax ID: 550856151
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No